# Relay Therapeutics, Inc.: financial statements, quarterly

RLAY · Nasdaq · CIK 1812364 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rlay.md) · [Financials](/companies/rlay/financials.md) · [Filings](/companies/rlay/filings.md) · [Insiders](/companies/rlay/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rlay/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [25.2](/filings/0000950170-24-122332.md) | [(0.0) d](/filings/0001193125-26-076739.md) | [10.0](/filings/0000950170-25-063553.md) | [0.0](/filings/0000950170-25-105054.md) | [0.0](/filings/0001193125-25-269601.md) | [0.0 d](/filings/0001193125-26-076739.md) | [7.7](/filings/0001193125-26-206454.md) | [0.7](/filings/0001193125-26-338056.md) | [0.0](/filings/0001193125-25-269601.md) | [7.0 d](/filings/0001193125-26-076739.md) | [3.0](/filings/0001193125-26-206454.md) | [0.4](/filings/0001193125-26-338056.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(73.6)](/filings/0000950170-24-122332.md) | [(92.2) d](/filings/0001193125-26-076739.md) | [(90.4)](/filings/0000950170-25-063553.md) | [(101)](/filings/0000950170-25-105054.md) | [(96.4)](/filings/0001193125-25-269601.md) | [(85.0) d](/filings/0001193125-26-076739.md) | [(84.9)](/filings/0001193125-26-206454.md) | [(76.8)](/filings/0001193125-26-338056.md) | [(80.4)](/filings/0001193125-25-269601.md) | [(60.6) d](/filings/0001193125-26-076739.md) | [(78.6)](/filings/0001193125-26-206454.md) | [(90.8)](/filings/0001193125-26-338056.md) |
| Net income | $m | [(65.7)](/filings/0000950170-24-122332.md) | [(83.5) d](/filings/0001193125-26-076739.md) | [(81.4)](/filings/0001193125-25-269601.md) | [(92.2)](/filings/0001193125-25-269601.md) | [(88.1)](/filings/0001193125-25-269601.md) | [(76.0) d](/filings/0001193125-26-076739.md) | [(77.1)](/filings/0001193125-26-338056.md) | [(70.4)](/filings/0001193125-26-338056.md) | [(74.1)](/filings/0001193125-25-269601.md) | [(54.9) d](/filings/0001193125-26-076739.md) | [(73.3)](/filings/0001193125-26-338056.md) | [(83.7)](/filings/0001193125-26-338056.md) |
| Diluted EPS | $ per share | [(0.54)](/filings/0000950170-24-122332.md) | not reported | [(0.62)](/filings/0000950170-25-063553.md) | [(0.69)](/filings/0000950170-25-105054.md) | [(0.63)](/filings/0001193125-25-269601.md) | not reported | [(0.46)](/filings/0001193125-26-206454.md) | [(0.41)](/filings/0001193125-26-338056.md) | [(0.43)](/filings/0001193125-25-269601.md) | not reported | [(0.41)](/filings/0001193125-26-206454.md) | [(0.41)](/filings/0001193125-26-338056.md) |
| Basic EPS | $ per share | [(0.54)](/filings/0000950170-24-122332.md) | not reported | [(0.62)](/filings/0000950170-25-063553.md) | [(0.69)](/filings/0000950170-25-105054.md) | [(0.63)](/filings/0001193125-25-269601.md) | not reported | [(0.46)](/filings/0001193125-26-206454.md) | [(0.41)](/filings/0001193125-26-338056.md) | [(0.43)](/filings/0001193125-25-269601.md) | not reported | [(0.41)](/filings/0001193125-26-206454.md) | [(0.41)](/filings/0001193125-26-338056.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [151](/filings/0000950170-24-122332.md) | [144](/filings/0000950170-25-027756.md) | [153](/filings/0000950170-25-063553.md) | [134](/filings/0000950170-25-105054.md) | [152](/filings/0001193125-25-269601.md) | [124](/filings/0001193125-26-076739.md) | [93.5](/filings/0001193125-26-206454.md) | [114](/filings/0001193125-26-338056.md) | [91.6](/filings/0001193125-25-269601.md) | [84.0](/filings/0001193125-26-338056.md) | [205](/filings/0001193125-26-206454.md) | [121](/filings/0001193125-26-338056.md) |
| Current assets | $m | [832](/filings/0000950170-23-058237.md) | [770](/filings/0000950170-25-027756.md) | [770](/filings/0000950170-24-052135.md) | [704](/filings/0000950170-24-091837.md) | [865](/filings/0000950170-24-122332.md) | [809](/filings/0001193125-26-076739.md) | [740](/filings/0000950170-25-063553.md) | [680](/filings/0000950170-25-105054.md) | [624](/filings/0001193125-25-269601.md) | [578](/filings/0001193125-26-338056.md) | [658](/filings/0001193125-26-206454.md) | [928](/filings/0001193125-26-338056.md) |
| Total assets | $m | [907](/filings/0000950170-23-058237.md) | [844](/filings/0000950170-25-027756.md) | [841](/filings/0000950170-24-052135.md) | [773](/filings/0000950170-24-091837.md) | [930](/filings/0000950170-24-122332.md) | [871](/filings/0001193125-26-076739.md) | [799](/filings/0000950170-25-063553.md) | [729](/filings/0000950170-25-105054.md) | [670](/filings/0001193125-25-269601.md) | [621](/filings/0001193125-26-338056.md) | [700](/filings/0001193125-26-206454.md) | [967](/filings/0001193125-26-338056.md) |
| Current liabilities | $m | [50.7](/filings/0000950170-23-058237.md) | [30.3](/filings/0000950170-25-027756.md) | [37.1](/filings/0000950170-24-052135.md) | [45.0](/filings/0000950170-24-091837.md) | [47.0](/filings/0000950170-24-122332.md) | [50.7](/filings/0001193125-26-076739.md) | [37.1](/filings/0000950170-25-063553.md) | [32.5](/filings/0000950170-25-105054.md) | [32.6](/filings/0001193125-25-269601.md) | [25.6](/filings/0001193125-26-338056.md) | [29.8](/filings/0001193125-26-206454.md) | [50.8](/filings/0001193125-26-338056.md) |
| Total liabilities | $m | [129](/filings/0000950170-23-058237.md) | [92.0](/filings/0000950170-25-027756.md) | [95.7](/filings/0000950170-24-052135.md) | [90.8](/filings/0000950170-24-091837.md) | [91.3](/filings/0000950170-24-122332.md) | [93.5](/filings/0001193125-26-076739.md) | [78.3](/filings/0000950170-25-063553.md) | [63.2](/filings/0000950170-25-105054.md) | [62.3](/filings/0001193125-25-269601.md) | [54.3](/filings/0001193125-26-338056.md) | [57.4](/filings/0001193125-26-206454.md) | [77.4](/filings/0001193125-26-338056.md) |
| Shareholders' equity | $m | [778](/filings/0000950170-24-122332.md) | [752](/filings/0001193125-26-076739.md) | [746](/filings/0001193125-25-269601.md) | [682](/filings/0001193125-25-269601.md) | [839](/filings/0001193125-25-269601.md) | [778](/filings/0001193125-26-338056.md) | [721](/filings/0001193125-26-338056.md) | [666](/filings/0001193125-26-338056.md) | [608](/filings/0001193125-25-269601.md) | [567](/filings/0001193125-26-338056.md) | [642](/filings/0001193125-26-338056.md) | [890](/filings/0001193125-26-338056.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(75.4) d](/filings/0000950170-24-122332.md) | [(89.2) d](/filings/0001193125-26-076739.md) | [(50.3)](/filings/0000950170-25-063553.md) | [(65.8) d](/filings/0000950170-25-105054.md) | [(75.1) d](/filings/0001193125-25-269601.md) | [(57.9) d](/filings/0001193125-26-076739.md) | [(73.2)](/filings/0001193125-26-206454.md) | [(55.3) d](/filings/0001193125-26-338056.md) | [(62.1) d](/filings/0001193125-25-269601.md) | [(44.9) d](/filings/0001193125-26-076739.md) | [(51.1)](/filings/0001193125-26-206454.md) | [(54.1) d](/filings/0001193125-26-338056.md) |
| Capital expenditure | $m | [0.6 d](/filings/0000950170-24-122332.md) | [0.1 d](/filings/0001193125-26-076739.md) | [1.8](/filings/0000950170-25-063553.md) | [0.0 d](/filings/0000950170-25-105054.md) | [0.2 d](/filings/0001193125-25-269601.md) | [0.0 d](/filings/0001193125-26-076739.md) | [0.4](/filings/0001193125-26-206454.md) | [0.0 d](/filings/0001193125-26-338056.md) | [(0.0) d](/filings/0001193125-25-269601.md) | [0.0 d](/filings/0001193125-26-076739.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2021 (2021-09-30) | Q3 FY2022 (2022-09-30) |
| --- | --- | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [92.7](/filings/0000950170-22-021892.md) | [111](/filings/0000950170-22-021892.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 219,141,631 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338056.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.